Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam-remifentanil PK/PD interaction study in healthy volunteers
NL-OMON51001Phase 1Active, not recruiting
- Sponsor
- PAION AG
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of remimazolam and remifentanil in general anesthesia (2 arms), sponsored by PAION AG. Primary endpoint: Exposure-response model for MOAA/S. Started Mar 2021; status: active, not recruiting.
02
Drugs
remimazolamremifentanil
03
Conditions
general anesthesia
Beyond the preview
Go deeper on NL-OMON51001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51001.